AbCellera Biologics Inc.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $75.1M | $28.8M | $38.0M | $485.4M | $375.2M | $233.2M | $11.6M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $186.8M | $167.3M | $175.7M | $107.9M | $62.1M | $29.4M | $10.1M |
| SG&A Expense | — | $83.2M | $85.5M | $75.2M | $55.5M | $41.8M | $11.9M | $2.7M |
| Operating Income | — | $-217.1M | $-314.8M | $-237.2M | $216.5M | $204.4M | $156.0M | $-4.1M |
| Operating Margin | — | -289.0% | -1,091.7% | -623.8% | 44.6% | 54.5% | 66.9% | -35.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-177.6M | $-200.4M | $-174.0M | $239.1M | $219.1M | $157.8M | $-2.2M |
| Income Tax Expense | — | $-31.2M | $-37.5M | $-27.6M | $80.6M | $65.7M | $38.9M | — |
| Net Income | — | $-146.4M | $-162.9M | $-146.4M | $158.5M | $153.5M | $118.9M | $-2.2M |
| Net Margin | — | -194.9% | -564.8% | -385.0% | 32.7% | 40.9% | 51.0% | -19.0% |
| EPS (Basic) | — | $-0.49 | $-0.55 | $-0.51 | $0.56 | $0.56 | $0.53 | $-0.01 |
| EPS (Diluted) | — | $-0.49 | $-0.55 | $-0.51 | $0.50 | $0.48 | $0.45 | $-0.01 |
| Shares Outstanding (Basic) | 303.2M | 298.7M | 294.3M | 289.2M | 285.1M | 275.8M | 159.2M | 151.3M |
| Shares Outstanding (Diluted) | 303.2M | 298.7M | 294.3M | 289.2M | 314.8M | 318.3M | 263.1M | 151.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |